Applications of TMDC NZs in different fields—starting from biosensing to different treatment fields like antibacterial, anti-inflammation activity and cancer therapy—are discussed in more details.
Applications | TMDCs Material | Activity Mimics | Targeting Molecule (if Any) | Therapeutic Mechanism | Therapeutic Mediators | Light Characteristics (if Involved) | Activity Assessed Against | In Vivo Evaluation | Ref. | |
---|---|---|---|---|---|---|---|---|---|---|
Microbial Cells | Mammalian Cells | |||||||||
Disinfection and wound healing | MoS2/rGO | POD-like, OD-like, CAT-like | ROS-mediated | H2O2 | Xenon lamp (100 mW/cm2) | Chloramphenicol-resistant E. coli and S. aureus | S. aureus-infected full-skin defect mice models | [52][20] | ||
Fe3O4@MoS2-Ag | POD-like | Ag+ ion-mediated toxicity, ROS-mediated, PTT | H2O2, Ag+ ions | NIR (808 nm, 1 W/cm2) | E. coli | [102][38] | ||||
citraconic anhydride modified PEI-MoS2 | POD-like | Disruption of surface charge, ROS-mediated | H2O2, 2-nitrobenzaldehyde | UV light (365 nm) | E. coli and S. aureus | E. coli and S. aureus-infected full-skin defect mice models | [89][24] | |||
WS2 QDs-Van@lipo | POD-like, OD-like | ROS-mediated, PTT, Chemotherapy | H2O2, vancomycine | NIR (808 nm, 1 W/cm2) | E. coli and Mu50 (vancomycin-intermediate S. aureus strain) | Mice models with Mu50-infected abscess | [60][25] | |||
Cu NW-supported MoS2 NS | POD-like | ROS-mediated, PTT | H2O2 | NIR (808 nm, 1 W/cm2) | E. coli and S. aureus | MRSA-infected full-skin defect mice models | [51][39] | |||
N-doped MoS2, N-doped WS2 | POD-like | ROS-mediated | H2O2 | Ampicillin resistant E. coli and B. subtilis | Ampicillin resistant E. coli-infected full-skin defect mice models | [42][40] | ||||
Lysozyme exfoliated MoS2 NSs | POD-like | ROS-mediated | H2O2 | Ampicillin-resistant E. coli and B. subtilis | [88][23] | |||||
PEG-MoS2 NFs | POD-like | ROS-mediated, Photothermal therapy (PTT) | H2O2 | NIR (808 nm, 1 W/cm2) | Ampicillin-resistant E. coli and B. subtilis | Ampicillin resistant E. coli-infected full-skin defect mice models | [90][26] | |||
CMSF-MoSe2 NSs | POD-like | ROS-mediated | H2O2 | E. coli and B. subtilis | E. coli-infected full-skin defect mice models | [87][22] | ||||
Anticancer therapy | Glucose responsive, TMZ-loaded chitosan-MoS2 | POD-like | ROS-mediated, GSH depletion, hypoxia induced TPZ activation | H2O2 and TPZ | A549 cells | A549 tumor-bearing mice models | [95][31] | |||
AuNBPs@MoS2 | POD-like | ROS-mediated, PTT | H2O2 | NIR laser (808 nm, 2.0 W/cm2) | HeLa cells | [97][33] | ||||
LNP-PEG-PEI coated, Dox loaded MoS2 NFs | POD-like | LNP nucleolar translocation signal peptide | ROS-mediated, CT, PTT, PDT | Dox | NIR laser (808 nm, 3.0 W/cm2) | 4T1 cells | 4T1 tumor-bearing mice models | [96][32] | ||
MoSe2/CoSe2@PEG | POD-like, CAT-like | ROS-mediated, GSH depletion, PTT | H2O2 | NIR laser (808 nm, 1.0 W/cm2) | HepG2 cells | Tumor-bearing mice models | [94][30] | |||
Cytoprotection | MoS2 NS | CAT-like, SOD-like, POD-like | Scavenging oxidative stress species | E. coli and S. aureus | A549 cells | [99][35] | ||||
Neurodegeneration | TPP-MoS2 QDs | CAT-like, SOD-like | TPP (mitochondrial targeting) | Scavenging oxidative stress species | BV-2 cells | Amyloid precursor protein/presenilin 1 (APP/PS1) double transgenic mice | [101][37] | |||
Osteoarthritis | Fullerene-like MoS2 | CAT-like, SOD-like | Scavenging oxidative stress species | HUVECs | [100][36] |